TIDMIXI

RNS Number : 8391K

IXICO plc

07 January 2021

IXICO plc

("IXICO" or the "Company")

Issue of Equity

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience , announces that it has made an application to the London Stock Exchange for the admission to trading on AIM of 45,176 new ordinary shares of 1p each ("New Shares") to satisfy the exercise of options.

The New Shares are expected to be admitted to trading on AIM on 12 January 2021.

Total voting rights

Application has been made for admission to trading on AIM of 45,176 New Shares. Admission of the New Shares on AIM is expected to become effective at 8.00 a.m. on 12 January 2021, following which there will be in total 47,136,468 ordinary shares in the capital of the Company in issue, each carrying equal voting rights.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, IXICO under the FCA's Disclosure and Transparency Rules.

For further information please contact:

 
 IXICO plc                                      +44 (0)20 3763 7498 
 Giulio Cerroni, Chief Executive Officer 
  Grant Nash, Chief Financial Officer 
 
 Cenkos Securities PLC (Nominated adviser 
  and sole broker)                              +44 (0)20 7397 8900 
 Giles Balleny / Max Gould (Corporate 
  Finance) 
 Michael F Johnson / Russell Kerr 
  (Sales 
 
 Walbrook PR Ltd                                +44 (0)20 7933 8780 
 Paul McManus / Lianne Cawthorne               IXICO@walbrookpr.com 
  / 
 Alice Woodings 
 
 

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

   More information is available on www.IXICO.com   and follow us on Twitter @IxicOplc 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEFLFVDLEIRIIL

(END) Dow Jones Newswires

January 07, 2021 02:00 ET (07:00 GMT)